Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis

Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis

Bibliographic Details
Main Authors:	Nicolino Ruperto, Ekaterina Alexeeva, Tamàs Constantin, Ivan Foeldvari, Angelo Ravelli, Gerd Horneff, Gaëlle Chédeville, Giovanni Filocamo, Alessandro Consolaro, Marco Burrone, Gabriella Giancane, Alessandra Alongi, Roberta Naddei, Valentina Natoli, Francesca Ridella, Silvia Rosina
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-03-01
Series:	RMD Open
Online Access:	https://rmdopen.bmj.com/content/8/1/e002042.full

Similar Items

Juvenile Psoriatic Arthritis: Myth or Reality? An Unending Debate
by: Roberta Naddei, et al.
Published: (2023-01-01)

A new approach to defining inactive disease, minimal disease activity and parent- and child-acceptable symptom state in juvenile idiopathic arthritis
by: Bertamino M, et al.
Published: (2011-09-01)

A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis
by: Cecilia Bava, et al.
Published: (2019-07-01)

IL-1 inhibition in systemic juvenile idiopathic arthritis
by: Gabriella Giancane, et al.
Published: (2016-12-01)

Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the “comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS” (STARS) trial
by: Marco Burrone, et al.
Published: (2022-09-01)

Consenso em reumatologia pediátrica: parte I - definição dos critérios de doença inativa e remissão em artrite idiopática juvenil/artrite reumatóide juvenil Consensus in pediatric rheumatology: part I - criteria definition of inactive disease and remission in juvenile idiopathic arthritis / juvenile rheumatoid arthritis
by: Claudia Machado, et al.
Published: (2005-02-01)

Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review
by: Gerd Horneff, et al.
Published: (2023-02-01)

Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study
by: Consolaro Alessandro, et al.
Published: (2012-11-01)

Comparison of the accuracy of different definitions of clinical remission (CR) and minimal disease activity (MDA) in juvenile idiopathic arthritis (JIA)
by: Davì S, et al.
Published: (2008-09-01)

Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era
by: Gabriella Giancane, et al.
Published: (2019-07-01)

Osteoid osteoma of the scaphoid bone mimicking juvenile idiopathic arthritis
by: Chédeville Gaëlle
Published: (2012-07-01)

Multisystem Inflammatory Syndrome in Children: Unique Disease or Part of the Kawasaki Disease Spectrum?
by: Caterina Matucci-Cerinic, et al.
Published: (2021-06-01)

Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
by: Cron Randy Q, et al.
Published: (2011-09-01)

Agreement between objective and subjective definitions of inactive disease, remission and minimal disease activity in juvenile idiopathic arthritis
by: Davì S, et al.
Published: (2011-09-01)

Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index
by: Carine Wouters, et al.
Published: (2024-02-01)

Preliminary validation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 403 clinic patients
by: Solari N, et al.
Published: (2008-09-01)

Development and initial validation of a new short and simple Health-Related Quality Of Life (HRQL) Questionnaire for Pediatric Rheumatic Diseases (PRD)
by: Palmisani E, et al.
Published: (2008-09-01)

Orbital myositis: a report of 3 pediatric cases
by: Chédeville Gaëlle, et al.
Published: (2012-07-01)

District Heating and Cooling towards Net Zero
by: Silvia Ravelli
Published: (2022-08-01)

Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)
by: Consolaro A, et al.
Published: (2008-09-01)

Consenso em reumatologia pediátrica: parte II - definição de melhora clínica para o lúpus eritematoso sistêmico e dermatomiosite juvenil Consensus in pediatric rheumatology: part II - definition of clinical improvement in systemic lupus erythematosus and juvenile dermatomyositis
by: Claudia Machado, et al.
Published: (2005-02-01)

Physical inactivity in Italian Society
by: Daniele Masala, et al.
Published: (2016-09-01)

Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries
by: Joost Swart, et al.
Published: (2018-12-01)

Do parent's global rating of well-being and disease activity of children with juvenile idiopathic arthritis yield different information?
by: Ullmann N, et al.
Published: (2008-09-01)

Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA)
by: Filocamo G, et al.
Published: (2008-09-01)

Distribution-Dependent Weighted Union Bound
by: Luca Oneto, et al.
Published: (2021-01-01)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
by: Gerd Horneff, et al.
Published: (2017-11-01)

Inactive at Home – Inactive Abroad: Civic Participation of Polish Migrants
by: Michał Nowosielski, et al.
Published: (2023-06-01)

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee
by: Gabriella Giancane, et al.
Published: (2020-04-01)

Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis
by: Meiorin S, et al.
Published: (2008-09-01)

Children with juvenile idiopathic arthritis currently followed in a tertiary care setting have a better psychosocial well-being than healthy peers
by: Suffia C, et al.
Published: (2011-09-01)

From Nearly Zero Energy to Carbon-Neutral: Case Study of a Hospitality Building
by: Francesco Causone, et al.
Published: (2021-10-01)

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
by: Ivan Foeldvari, et al.
Published: (2019-05-01)

Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry
by: Joeri W. van Straalen, et al.
Published: (2022-11-01)

Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis
by: Buoncompagni Antonella, et al.
Published: (2007-12-01)

Islamisation in action not inaction
by: Hassan, Mohd. Kamal
Published: (2013)

The Sin and Guilt of Inaction
by: Dallas Ducar
Published: (2014-03-01)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
by: Horneff G, et al.
Published: (2008-09-01)

Baricitinib in therapy of COPA syndrome in a 15-year-old girl
by: Sophia Krutzke, et al.
Published: (2020-02-01)

Characterization and preservations of the variance inactivity time ordering and the increasing variance inactivity time class
by: Mervat Mahdy
Published: (2012-01-01)